An early open-label phase 2 study of mild-to-moderate COVID-19 patients showed that treatment with subcutaneous injection of IFN-β1b, within 7 days from symptoms onset, combined with oral lopinavir-ritonavir and ribavirin was safe and superior to therapy without IFN administration in shortening the time to symptoms alleviation, the duration of SARS-CoV-2-RNA positivity tested in nasopharyngeal swab and hospital stay period. This evidence concerns the gene IFNA1 and COVID-19.